Tonight's Highlights: Core Inflation Moderates in April; Equity Futures Soften as Oil Rebounds; Snowflake Surges 38%
US stock index futures drifted lower Thursday as a minor rebound in crude pricing cooled risk appetite, tracking broad-based pullbacks across major European benchmarks.
Pre-market data showed the Federal Reserve’s preferred inflation metric, the Personal Consumption Expenditures (PCE) price index, advanced at a 3.8% annualized clip in April, matching consensus estimates.
On a month-over-month basis, the headline PCE index stepped up 0.4%, slightly cooler than the 0.5% forecast.
More encouragingly, the core PCE price index—which strips out volatile food and energy inputs—rose 3.3% year-over-year, in line with consensus. The monthly core print ticked up 0.2%, undercutting Wall Street estimates of 0.3%.
Sovereign energy premiums crept higher following reports that US forces executed a fresh round of targeted military strikes against a strategic installation in southern Iran.
President Donald Trump noted Wednesday that Washington remains committed to securing a diplomatic framework to normalize maritime transit through the Strait of Hormuz and neutralize Iran’s highly enriched uranium stockpiles.
However, this latest cross-border military friction is severely testing a highly fragile ceasefire.
The down-tick follows a blockbuster Wednesday session where the Dow Jones Industrial Average clinched fresh intraday and closing all-time highs, propelled by an initial cooling in crude prices.
In corporate moving names, cloud data giant Snowflake Inc. skyrocketed 38% pre-market.
The software heavyweight delivered a comprehensive beat-and-raise quarterly print, posting top- and bottom-line metrics that handily cleared Wall Street expectations for the first fiscal quarter while raising its Q2 guidance.
Furthermore, Snowflake committed to a massive $6 billion infrastructure spend with Amazon Web Services (AWS) over the next five years.
The stellar execution effectively calmed pervasive market anxieties that generative AI workflows would cannibalize Snowflake's core data-warehousing architecture, positioning the equity to recoup steep losses suffered during the recent "SaaS apocalyptic sell-off."
Throughout the year, software valuations have been heavily compressed by macro fears that rapid AI adoption would permanently disrupt traditional enterprise cloud software models.
Corporate Highlights
Meta Reportedly Outlines New "Enterprise Solutions" Arm for Bespoke Corporate AI Integration
According to an internal corporate memorandum, Meta Platforms Inc. is finalizing plans to establish a dedicated business unit tasked with engineering bespoke artificial intelligence applications for corporate client portfolios.
The new division, branded Enterprise Solutions, will embed specialized product managers and systems engineers to streamline the integration of Meta's proprietary AI tooling across enterprise networks, establishing repeatable operational playbooks to scale the layout over time.
Toyota Global April Sales Slide for Third Consecutive Month; Middle East Shipments Plunge 91%
Toyota Motor Corp. operational data released May 28 showed global sales volume dropped 3.1% year-over-year to 849,300 vehicles in April, marking its third straight monthly contraction.
Conversely, global manufacturing output edged up 2.0% to 832,000 units, expanding for a second month to hit a record high for the month of April.
Crucially, Toyota's vehicle export volume from Japan to the Middle East cratered 91.7% year-over-year to just 2,418 units, accelerating a structural export downturn following March's 46.4% retreat.
Robinhood Unveils AI-Driven Trading Infrastructure via Autonomous Bot API Portals
Digital brokerage pioneer Robinhood Markets Inc. announced Wednesday that users opening its newly minted "agent-based trading accounts" will be permitted to grant execution authorization to advanced AI models, including Anthropic’s Claude Code and OpenAI’s ChatGPT.
The structural upgrade empowers autonomous algorithms to build custom portfolios, formalize quantitative trading strategies, and route trade orders directly into the market infrastructure.
Eli Lilly Publishes Definitive Tirzepatide Data Outlining Compounding Clinical Benefits of Early Intervention
Eli Lilly & Co. has published full clinical results from its SURPASS-EARLY trial, tracking the therapeutic impact of early-stage intervention in newly diagnosed Type 2 diabetes patients.
The rigorous two-year follow-up study demonstrated that patients treated with tirzepatide recorded significantly greater glycemic control compared to standard intensive standard-of-care regimens.
Notably, 60% of the tirzepatide cohort achieved euglycemia (normal blood sugar thresholds), vastly outperforming the 24% baseline in the control group.
Beyond superior glucose management, the tirzepatide arm logged outsized reductions in body weight and waist circumference, alongside marked improvements across systemic metabolic markers including lipid profiles, beta-cell function, and insulin sensitivity.